Rancho Santa Fe, CA, United States of America

Stuart Arthur Lipton

This inventor holds 27 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Neuroprotective Compositions. Top assignees: Children's Medical Center Corporation, Sanford-Burnham Medical Research Institute, The Brigham and Women's Hospital, Inc.. Active years: 1982-2024.

USPTO Granted Patents = 27 (Patent Applications = 8)

% Patents Active = 74.1

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 1.6

ph-index = 11

Forward Citations = 427(Granted Patents)

Location History:

Brookline, MA (US) (1982)
Newton, MA (US) (1991 - 2006)
La Jolla, CA (US) (2011 - 2013)
Rancho Santa Fe, CA (US) (2002 - 2024)

Company Filing History:

11 out of 1,072

Children's Medical Center Corporation

patents

5 out of 99

Sanford-Burnham Medical Research Institute

patents

4 out of 1,425

The Brigham and Women's Hospital, Inc.

patents

4. 2 out of 55

Burnham Institute for Medical Research

patents

5. 2 out of 276

Massachusetts Eye and Ear Infirmary

Adamas Pharmaceuticals, Inc.

patents

9. 1 out of 11

Panorama Research Inc.

patents

10. 3 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1982-2024

Loading Chart...

Areas of Expertise:

Aminoadamantane Derivatives

Neuroprotective Synergy

CNS Disorders

Glaucoma Treatment

NMDA Receptor

Erythropoietin

Insulin-Like Growth Factors

p38/MEF2 Pathway

Cell Differentiation

Neuronal Damage

Therapeutic Agents

Beta-Hydroxybutyrate

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071392 - Aminoadamantyl nitrate compounds and their use to treat CNS disorders (2024-08-27),

2. 11529319 - Methods and compositions for treating neurological conditions (2022-12-20),

3. 8466311 - Neuroprotective compositions and methods (2013-06-18),

4. 8236563 - Methods of differentiating and protecting cells by modulating the p38/MEF2 pathway (2012-08-07),

5. 8193315 - Excitatory glycine receptors and methods (2012-06-05),

6. 8022246 - Neuroprotective compositions and methods (2011-09-20),

7. 7919317 - Methods of differentiating and protecting cells by modulating the P38/MEF2 pathway (2011-04-05),

8. 7790404 - Excitatory glycine receptors and methods (2010-09-07),

9. 7439063 - Neuroprotective synergy of erythropoietin and insulin-like growth factors (2008-10-21),

10. 7326730 - Aminoadamantane derivatives as therapeutic agents (2008-02-05),

11. 7091329 - Protein 68075 and its use for regenerating nerve cell processes (2006-08-15),

12. 6620845 - Aminoadamantane derivatives as therapeutic agents (2003-09-16),

13. 6525017 - Using glutathiane to protect neurons from injury (2003-02-25),

14. 6503947 - Method of treating cytotoxic damage (2003-01-07),

15. 6482854 - Glaucoma treatment (2002-11-19),

Title: **Stuart Arthur Lipton: Innovator in CNS Disorder Treatments**

Introduction

Stuart Arthur Lipton is a notable inventor based in Rancho Santa Fe, California. He holds a significant patent that showcases his contribution to the field of medicine, particularly in treating central nervous system disorders.

Latest Patents

His patented invention, titled "Aminoadamantyl Nitrate Compounds and Their Use to Treat CNS Disorders," presents a novel approach to addressing various neurological challenges. The patent highlights adamantyl compounds that feature one or more amine groups alongside one or more nitrate groups. These aminoadamantyl nitrate compounds are specifically developed to combat disorders related to the central nervous system, including both neurodegenerative and non-neurodegenerative diseases.

Career Highlights

Stuart Arthur Lipton has made significant strides in his career, working with Panorama Research Inc. This role has enabled him to contribute valuable research and innovation in the medical field, focusing on enhancing treatments for complex neurological conditions.

Collaborations

Throughout his work, Stuart has collaborated with esteemed colleagues such as Cyrus K. Becker and Meenakshi S. Venkatraman. These collaborations have fostered a productive environment for innovation, enabling the development of effective therapeutic solutions.

Conclusion

Stuart Arthur Lipton’s inventive contributions underscore the importance of innovation in medical research and the potential to transform treatments for central nervous system disorders. His work continues to impact the field, paving the way for advancements that can improve the quality of life for many individuals facing neurological challenges.